Credit Suisse Ag Taysha Gene Therapies, Inc. Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.47 - $6.77 $37,516 - $102,829	-15,189 Reduced 99.92%	12 $0
Q1 2022 May 16, 2022	BUY	$5.22 - $11.86 $2,322 - $5,277	445 Added 3.02%	15,201 $99,000
Q4 2021 Feb 14, 2022	BUY	$11.43 - $19.2 $14,904 - $25,036	1,304 Added 9.69%	14,756 $172,000
Q3 2021 Nov 12, 2021	BUY	$15.82 - $21.57 $996 - $1,358	63 Added 0.47%	13,452 $249,000
Q2 2021 Aug 16, 2021	BUY	$19.29 - $26.38 $258,273 - $353,201	13,389 New	13,389 $283,000

117

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $85.1M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.